Your browser is no longer supported. Please, upgrade your browser.
VNDA [NASD]
Vanda Pharmaceuticals Inc.
Index- P/E32.95 EPS (ttm)0.57 Insider Own3.30% Shs Outstand55.15M Perf Week4.42%
Market Cap1.02B Forward P/E23.46 EPS next Y0.80 Insider Trans-19.49% Shs Float53.10M Perf Month11.14%
Income31.50M PEG- EPS next Q0.14 Inst Own- Short Float9.61% Perf Quarter2.30%
Sales252.80M P/S4.05 EPS this Y-79.90% Inst Trans2.17% Short Ratio10.80 Perf Half Y42.58%
Book/sh8.48 P/B2.20 EPS next Y29.27% ROA6.00% Target Price24.00 Perf Year65.34%
Cash/sh6.89 P/C2.71 EPS next 5Y- ROE7.00% 52W Range9.00 - 20.51 Perf YTD41.93%
Dividend- P/FCF16.96 EPS past 5Y19.60% ROI4.20% 52W High-9.07% Beta0.43
Dividend %- Quick Ratio6.80 Sales past 5Y17.70% Gross Margin90.40% 52W Low107.22% ATR0.61
Employees292 Current Ratio6.80 Sales Q/Q8.10% Oper. Margin14.90% RSI (14)71.23 Volatility3.84% 3.43%
OptionableYes Debt/Eq0.00 EPS Q/Q94.30% Profit Margin12.50% Rel Volume0.69 Prev Close18.41
ShortableYes LT Debt/Eq0.00 EarningsMay 05 AMC Payout0.00% Avg Volume472.39K Price18.65
Recom1.00 SMA209.03% SMA5010.68% SMA20036.60% Volume328,071 Change1.30%
May-12-21Initiated BofA Securities Buy $22
Jan-14-21Downgrade Citigroup Buy → Neutral $14
Oct-29-20Upgrade Citigroup Neutral → Buy $14
Jun-09-20Downgrade Citigroup Buy → Neutral $14
Mar-16-20Downgrade Oppenheimer Perform → Underperform
Mar-12-20Upgrade Citigroup Neutral → Buy $14
Nov-07-19Downgrade Citigroup Buy → Neutral $19
Aug-01-19Upgrade Citigroup Neutral → Buy $19
Jul-25-19Downgrade Stifel Buy → Hold $26 → $17
Dec-11-18Downgrade Oppenheimer Outperform → Perform
Dec-04-18Upgrade Cantor Fitzgerald Neutral → Overweight
Dec-04-18Reiterated Jefferies Buy $30 → $40
Nov-08-18Resumed Jefferies Buy
Sep-21-18Resumed Oppenheimer Outperform
May-23-18Initiated Citigroup Buy $26
Jan-19-18Initiated Seaport Global Securities Buy $20
Sep-14-17Reiterated Piper Jaffray Overweight $23 → $26
Jun-27-17Resumed Piper Jaffray Overweight $23
May-26-17Initiated H.C. Wainwright Buy $18
Apr-12-17Initiated Oppenheimer Outperform $21
May-12-21 04:30PM  
May-07-21 10:25AM  
May-06-21 09:53PM  
May-05-21 09:30PM  
06:15PM  
04:01PM  
02:45PM  
May-04-21 07:30AM  
Apr-29-21 09:01PM  
Apr-28-21 12:34PM  
Apr-25-21 02:00AM  
Apr-20-21 04:30PM  
Apr-16-21 10:50PM  
02:33PM  
Apr-13-21 08:15AM  
Apr-06-21 06:40AM  
Mar-23-21 07:15AM  
Mar-18-21 04:26PM  
09:11AM  
Mar-17-21 01:56PM  
Mar-12-21 10:50PM  
Mar-11-21 01:52PM  
Feb-23-21 02:49PM  
Feb-14-21 01:32PM  
Feb-12-21 12:54AM  
Feb-11-21 10:28AM  
Feb-10-21 08:30PM  
04:28PM  
04:01PM  
07:34AM  
Feb-02-21 04:30PM  
Dec-19-20 06:11PM  
Dec-02-20 03:02PM  
07:35AM  
Dec-01-20 06:00PM  
04:47AM  
Nov-17-20 12:43PM  
Oct-29-20 09:31AM  
Oct-28-20 05:55PM  
04:01PM  
02:30PM  
Oct-26-20 04:01PM  
Oct-21-20 04:45PM  
Oct-13-20 01:14PM  
Oct-02-20 01:44PM  
Sep-15-20 03:41PM  
Aug-31-20 06:30PM  
Aug-18-20 10:24AM  
07:00AM  
Aug-06-20 08:21PM  
Aug-05-20 06:05PM  
04:01PM  
Aug-03-20 08:53AM  
07:00AM  
Jul-29-20 05:00PM  
Jul-22-20 12:32PM  
Jul-21-20 04:04PM  
Jul-14-20 11:02AM  
08:04AM  
Jul-13-20 04:30PM  
Jun-19-20 02:38PM  
May-26-20 07:00AM  
May-21-20 05:08PM  
May-20-20 05:20PM  
10:45AM  
May-15-20 11:43AM  
May-14-20 07:03AM  
May-13-20 07:00AM  
May-08-20 07:32PM  
May-07-20 11:31AM  
May-06-20 06:45PM  
Apr-29-20 04:05PM  
12:34PM  
Apr-27-20 02:18PM  
Apr-23-20 09:12AM  
Apr-22-20 01:01PM  
Apr-21-20 05:14PM  
Apr-17-20 10:00AM  
08:54AM  
Apr-16-20 10:58AM  
08:09AM  
Apr-15-20 04:15PM  
04:05PM  
Apr-09-20 07:52AM  
Apr-08-20 04:05PM  
Apr-03-20 02:26PM  
Apr-02-20 01:36PM  
Mar-19-20 12:59PM  
Mar-10-20 05:13PM  
Feb-27-20 05:35PM  
Feb-26-20 03:05PM  
Feb-25-20 04:13PM  
04:01PM  
Feb-21-20 12:26PM  
Feb-19-20 07:00AM  
Feb-18-20 08:22PM  
Feb-05-20 09:15AM  
Feb-03-20 03:28PM  
Jan-31-20 06:24PM  
Jan-16-20 02:57PM  
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; and a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Jones Aranthan IIChief Corp. Affairs OfficerMar 15Option Exercise11.3215,000169,800111,935Mar 16 04:20 PM
Jones Aranthan IIChief Corp. Affairs OfficerMar 15Sale17.7218,000319,01093,935Mar 16 04:20 PM
Polymeropoulos Mihael HristosPresident and CEOMar 08Sale18.00175,0003,150,0521,221,062Mar 09 05:15 PM
Williams TimothySVP & General CounselMar 05Sale17.855,60099,96686,926Mar 08 05:47 PM
Williams TimothySVP & General CounselMar 02Sale18.547,674142,30792,526Mar 03 06:43 PM
Wijkstrom JoakimSVP, Chief Marketing OfficerMar 02Sale18.453,88871,72978,202Mar 03 06:42 PM
Polymeropoulos Mihael HristosPresident and CEOMar 02Sale18.3415,206278,9021,396,062Mar 03 06:41 PM
Jones Aranthan IIChief Corp. Affairs OfficerMar 02Sale18.043,86569,71796,935Mar 03 06:40 PM
Moran Kevin PatrickSVP, CFO & TreasurerMar 02Sale18.236,044110,191101,426Mar 03 06:40 PM
Birznieks GuntherSVP, Business DevelopmentMar 02Sale18.1916,620302,273171,708Mar 03 06:39 PM
Williams TimothySVP & General CounselMar 01Sale18.6011,856220,543100,200Mar 03 06:43 PM
Polymeropoulos Mihael HristosPresident and CEOMar 01Sale18.457,479138,0031,411,268Mar 03 06:41 PM
Moran Kevin PatrickSVP, CFO & TreasurerMar 01Sale18.573,32761,780107,470Mar 03 06:40 PM
Birznieks GuntherSVP, Business DevelopmentMar 01Sale18.663,84571,744188,328Mar 03 06:39 PM
Jones Aranthan IIChief Corp. Affairs OfficerFeb 24Option Exercise12.2722,499276,063123,786Feb 26 05:17 PM
Jones Aranthan IIChief Corp. Affairs OfficerFeb 24Sale20.0122,986460,033100,800Feb 26 05:17 PM
DUGAN RICHARD WDirectorFeb 16Option Exercise7.1115,000106,65060,641Feb 18 08:43 PM
Watkins ThomasDirectorFeb 16Option Exercise7.1115,000106,65055,323Feb 18 08:43 PM
Watkins ThomasDirectorFeb 16Sale18.545,818107,85649,505Feb 18 08:43 PM
DUGAN RICHARD WDirectorFeb 16Sale18.545,754106,66354,887Feb 18 08:43 PM
Polymeropoulos Mihael HristosPresident and CEODec 15Option Exercise8.7546,663408,3011,342,897Dec 15 04:24 PM
Polymeropoulos Mihael HristosPresident and CEODec 15Sale13.0039,150508,8441,303,747Dec 15 04:24 PM
Polymeropoulos Mihael HristosPresident and CEODec 14Option Exercise8.7561,520538,3001,347,283Dec 15 04:24 PM
Polymeropoulos Mihael HristosPresident and CEODec 14Sale13.1951,049673,3061,296,234Dec 15 04:24 PM
Polymeropoulos Mihael HristosPresident and CEODec 11Option Exercise8.7541,817365,8991,320,816Dec 15 04:24 PM
Polymeropoulos Mihael HristosPresident and CEODec 11Sale12.8835,053451,3601,285,763Dec 15 04:24 PM
Wijkstrom JoakimSVP, Chief Marketing OfficerAug 20Sale11.083,71041,10956,290Aug 21 06:08 PM
Williams TimothySVP & General CounselAug 14Sale11.813,68443,52679,356Aug 17 04:42 PM
Jones Aranthan IIChief Corp. Affairs OfficerAug 12Sale11.817,20085,01875,487Aug 14 04:39 PM
Jones Aranthan IIChief Corp. Affairs OfficerJul 27Sale10.627,31377,63182,687Jul 29 08:17 PM
Watkins ThomasDirectorMay 29Option Exercise7.3815,000110,70045,000Jun 02 04:13 PM
Watkins ThomasDirectorMay 29Sale11.509,677111,28635,323Jun 02 04:13 PM
DUGAN RICHARD WDirectorMay 28Option Exercise7.3815,000110,70050,770May 29 04:10 PM
DUGAN RICHARD WDirectorMay 28Sale11.0410,129111,80640,641May 29 04:10 PM